» Authors » Danielle McCartney

Danielle McCartney

Explore the profile of Danielle McCartney including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 48
Citations 454
Followers 0
Related Specialties
Top 10 Co-Authors
Published In
Affiliations
Soon will be listed here.
Recent Articles
1.
Zhou C, Lavender I, Gordon R, McCartney D, Kevin R, Bedoya-Perez M, et al.
Sci Rep . 2025 Feb; 15(1):2649. PMID: 39905040
The Australian Capital Territory (ACT), a region that includes Australia's capital, Canberra, decriminalised small-scale cannabis cultivation and possession in January 2020. Here, we examined cannabis use and cultivation behaviours, experiences...
2.
McCartney D, Zhou C, Lavender I, Gordon R, Kevin R, Bedoya-Perez M, et al.
Drug Alcohol Rev . 2025 Jan; 44(2):588-601. PMID: 39778038
Introduction: In January 2020, the government of the Australian Capital Territory (ACT) decriminalised the possession and cultivation of cannabis for personal use. This study explored the driving-related attitudes, beliefs and...
3.
McCartney D, Irwin C, Bawa Z, Palmer B, Sahinovic A, Delang N, et al.
Sports Med Open . 2024 May; 10(1):61. PMID: 38782848
Background: Exercise is known to improve health. However, it can be unpleasant, often inducing negative feelings, or 'affect'. Cannabidiol (CBD), a non-intoxicating constituent of the cannabis plant, has been reported...
4.
Suraev A, McCartney D, Marshall N, Irwin C, Vandrey R, Grunstein R, et al.
Psychopharmacology (Berl) . 2024 May; 241(9):1815-1825. PMID: 38758300
Cannabis and its major constituents, Δ-tetrahydrocannabinol (THC) and cannabidiol (CBD), are being widely used to treat sleep disturbances. However, THC can cause acute cognitive and psychomotor impairment and there are...
5.
Bawa Z, McCartney D, Bedoya-Perez M, Lau N, Fox R, MacDougall H, et al.
BMJ Open . 2024 Mar; 14(3):e082927. PMID: 38531572
Introduction: The non-intoxicating plant-derived cannabinoid, cannabidiol (CBD), has demonstrated therapeutic potential in a number of clinical conditions. Most successful clinical trials have used relatively high (≥300 mg) oral doses of...
6.
Suraev A, McCartney D, Kevin R, Gordon R, Grunstein R, Hoyos C, et al.
Drug Test Anal . 2024 Feb; 16(12):1487-1495. PMID: 38414100
Point-of-collection testing (POCT) devices are widely used in roadside and workplace drug testing to identify recent cannabis use by measuring the presence of Δ-tetrahydrocannabinol (THC) in oral fluid (OF). However,...
7.
Delang N, Irwin C, Peek A, McGregor I, Desbrow B, McCartney D
J Neurochem . 2023 Nov; 167(5):615-632. PMID: 37908148
The aim of this study was to systematically review prior research investigating the effects of contact/collision sport participation on neurometabolite levels in the absence of concussion. Four online databases were...
8.
Lavender I, McCartney D, Marshall N, Suraev A, Irwin C, DRozario A, et al.
BMJ Open . 2023 Aug; 13(8):e071148. PMID: 37612115
Objective: Insomnia is the most prevalent sleep disorder, with few effective pharmacotherapies. Anecdotal reports and recent preclinical research suggest that cannabinol (CBN), a constituent of derived from delta-9-tetrahydrocannabinol, could be...
9.
Bawa Z, McCartney D, Manocha R, McGregor I
BMC Prim Care . 2022 Dec; 23(1):330. PMID: 36529730
Background: Medicinal cannabis (MC) products have been available on prescription in Australia for around six years. General practitioners (GPs) are at the forefront of MC prescribing and recent years have...
10.
McCartney D, Kevin R, Suraev A, Sahinovic A, Doohan P, Bedoya-Perez M, et al.
Drug Test Anal . 2022 Dec; 15(3):334-344. PMID: 36478641
A growing number of clinical trials (CTs) are investigating the therapeutic potential of cannabidiol (CBD), a non-intoxicating phytocannabinoid found in Cannabis sativa. These CTs often use crossover experimental designs requiring...